{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:30Z","timestamp":1792782510826,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Oriental Talents Program Youth Project","award":["SSF828085"],"award-info":[{"award-number":["SSF828085"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12275057"],"award-info":[{"award-number":["12275057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102097"],"award-info":[{"award-number":["82102097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Isotope Engineering Technology Research Center Funding","award":["GJTWSGCZX-202306"],"award-info":[{"award-number":["GJTWSGCZX-202306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07704-2","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:03:02Z","timestamp":1766019782000},"page":"3607-3621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical evaluation of 68Ga- and 177Lu-Labeled AP-01 for the targeted treatment of prostate cancer with moderate PSMA expression"],"prefix":"10.1007","volume":"53","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"5","key":"7704_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","volume":"8","author":"B Sheehan","year":"2022","unstructured":"Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 2022;8(5):1157\u201368.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"7704_CR2","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7704_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","volume":"25","author":"JR Mesters","year":"2006","unstructured":"Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006;25(6):1375\u201384.","journal-title":"EMBO J"},{"issue":"2","key":"7704_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1162\/153535002320162750","volume":"1","author":"MG Pomper","year":"2002","unstructured":"Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP. 11c-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2002;1(2):96\u2013101.","journal-title":"Mol Imaging"},{"issue":"6","key":"7704_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi KA, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [(177)lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"issue":"10","key":"7704_CR6","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [(177)lu]lu-PSMA-617 (pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15(10):1292.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"7704_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"7704_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/PAI.0000000000000110","volume":"23","author":"MC Tsourlakis","year":"2015","unstructured":"Tsourlakis MC, Klein F, Kluth M, Quaas A, Graefen M, Haese A, Simon R, Sauter G, Schlomm T, Minner S. PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol. 2015;23(6):449\u201355.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"7704_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/ar020073i","volume":"38","author":"SM Johnson","year":"2005","unstructured":"Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38(12):911\u201321.","journal-title":"Acc Chem Res"},{"issue":"97","key":"7704_CR10","doi-asserted-by":"publisher","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","volume":"3","author":"MM Alhamadsheh","year":"2011","unstructured":"Alhamadsheh MM, Connelly S, Cho A, Reixach N, Powers ET, Pan DW, Wilson IA, Kelly JW, Graef IA. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med. 2011;3(97):97ra81.","journal-title":"Sci Transl Med"},{"issue":"2","key":"7704_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00259-018-4204-z","volume":"46","author":"S Frangos","year":"2019","unstructured":"Frangos S, Buscombe JR. Why should we be concerned about a g? Eur J Nucl Med Mol Imaging. 2019;46(2):519.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7704_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","volume":"45","author":"I Virgolini","year":"2018","unstructured":"Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7704_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA, Mendiratta P, Barata PC, Jia AY, Spratt DE, Brown JR. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther. 2023;23(7):731\u201344.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10459","key":"7704_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Flechon A, Wei XX, Mahammedi H, Roubaud G, Studentova H, Nagarajah J, Mellado B, Montesa-Pino A, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. (177)lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"3","key":"7704_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63(3):415\u201323.","journal-title":"J Nucl Med"},{"issue":"9","key":"7704_CR16","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","volume":"29","author":"Z Wang","year":"2018","unstructured":"Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O, Chen X. Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem. 2018;29(9):3213\u201321.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"7704_CR17","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/thno.40482","volume":"10","author":"LM Deberle","year":"2020","unstructured":"Deberle LM, Benesova M, Umbricht CA, Borgna F, Buchler M, Zhernosekov K, Schibli R, Muller C. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10(4):1678\u201393.","journal-title":"Theranostics"},{"issue":"11","key":"7704_CR18","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","volume":"15","author":"HT Kuo","year":"2018","unstructured":"Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Benard F. Enhancing treatment efficacy of (177)lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15(11):5183\u201391.","journal-title":"Mol Pharm"},{"key":"7704_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.nu.14.070194.002431","volume":"14","author":"Y Ingenbleek","year":"1994","unstructured":"Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495\u2013533.","journal-title":"Annu Rev Nutr"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07704-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:11Z","timestamp":1777274771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07704-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7704"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07704-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was granted by the Ethics Committee of Fudan University Shanghai Cancer Center (No. 2019 Cancer Research JS-147).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors report no conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}